M. Rudwaleit, New approaches to diagnosis and classification of axial and peripheral spondyloarthritis, Curr Opin Rheumatol, vol.22, pp.375-380, 2010.

R. Van-den-berg and D. M. Van-der-heijde, How should we diagnose spondyloarthritis according to the ASAS classification criteria: a guide for practicing physicians, Pol Arch Med Wewn, vol.120, pp.452-457, 2010.

M. Rudwaleit, D. Van-der-heijde, and R. Landewe, The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection, Ann Rheum Dis, vol.68, pp.777-783, 2009.

M. Rudwaleit, D. Van-der-heijde, and R. Landewe, The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general, Ann Rheum Dis, vol.70, pp.25-31, 2011.

C. Papagoras and A. Drosos, Seronegative spondyloarthropathies: evolving concepts regarding diagnosis and treatment, J Spine, vol.1, p.102, 2012.

I. Essers, S. Ramiro, and C. Stolwijk, Characteristics associated with the presence and development of extra-articular manifestations in ankylosing spondylitis: 12-year results from OASIS, Rheumatology (Oxford), vol.54, pp.633-640, 2015.

C. Stolwijk, I. Essers, and A. Van-tubergen, The epidemiology of extra-articular manifestations in ankylosing spondylitis: a population-based matched cohort study, Ann Rheum Dis, vol.74, pp.1373-1378, 2015.

C. Stolwijk, A. Van-tubergen, and J. D. Castillo-ortiz, Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis, Ann Rheum Dis, vol.74, pp.65-73, 2015.

S. L. Zagora and P. Mccluskey, Ocular manifestations of seronegative spondyloarthropathies, Curr Opin Ophthalmol, vol.25, pp.495-501, 2014.

, Biologics and HLA-B27-associated Ocular Disorders

E. B. Suhler, T. M. Martin, and J. T. Rosenbaum, HLA-B27-associated uveitis: overview and current perspectives, Curr Opin Ophthalmol, vol.14, pp.378-383, 2003.

J. H. Chang, P. J. Mccluskey, and D. Wakefield, Acute anterior uveitis and HLA-B27, Surv Ophthalmol, vol.50, pp.364-388, 2005.

H. S. Uy, W. G. Christen, and C. S. Foster, HLA-B27-associated uveitis and cystoid macular edema, Ocul Immunol Inflamm, vol.9, pp.177-183, 2001.

E. M. Dodds, C. Y. Lowder, and D. M. Meisler, Posterior segment inflammation in HLA-B27+ acute anterior uveitis: clinical characteristics, Ocul Immunol Inflamm, vol.7, pp.85-92, 1999.

F. H. Verhagen, A. H. Brouwer, and J. J. Kuiper, Potential Predictors of Poor Visual Outcome in Human Leukocyte Antigen-B27-Associated Uveitis, Am J Ophthalmol, vol.165, pp.179-187, 2016.

D. Wakefield, J. H. Chang, and S. Amjadi, What is new HLA-B27 acute anterior uveitis?, Ocul Immunol Inflamm, vol.19, pp.139-144, 2011.

M. Dougados, F. Berenbaum, and A. Maetzel,

, Rev Rhum Ed Fr, vol.60, pp.81-83, 1993.

J. M. Benitez-del-castillo, J. Garcia-sanchez, and T. Iradier, Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis, Eye (Lond), vol.14, pp.340-343, 2000.

S. Munoz-fernandez, V. Hidalgo, and J. Fernandez-melon, Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period, J Rheumatol, vol.30, pp.1277-1279, 2003.

J. Braun and J. Sieper, Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches, Arthritis Res, vol.4, pp.307-321, 2002.

F. Lian, J. Zhou, and C. Wei, Anti-TNFalpha agents and methotrexate in spondyloarthritis related uveitis in a Chinese population, Clin Rheumatol, vol.34, pp.1913-1920, 2015.

S. Munoz-fernandez, A. M. Garcia-aparicio, and M. V. Hidalgo, Methotrexate: an option for preventing the recurrence of acute anterior uveitis, Eye (Lond), vol.23, pp.1130-1133, 2009.

J. M. Kezic, M. P. Davey, and T. T. Glant, Interferon-gamma regulates discordant mechanisms of uveitis versus joint and axial disease in a murine model resembling spondylarthritis, Arthritis Rheum, vol.64, pp.762-771, 2012.

A. Beck and J. M. Reichert, Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry, MAbs, vol.5, pp.621-623, 2013.

K. Traynor, FDA approves biosimilar version of infliximab, Am J Health Syst Pharm, vol.73, pp.604-606, 2016.

R. A. Rader, Re)defining biopharmaceutical, Nat Biotechnol, vol.26, pp.743-751, 2008.

G. Walsh, Biopharmaceuticals and biotechnology medicines: an issue of nomenclature, Eur J Pharm Sci, vol.15, pp.135-138, 2002.

S. Pasadhika and J. T. Rosenbaum, Update on the use of systemic biologic agents in the treatment of noninfectious uveitis, Biologics, vol.8, pp.67-81, 2014.

T. Morrow and L. H. Felcone, Defining the difference: What Makes Biologics Unique, Biotechnol Healthc, vol.1, pp.24-29, 2004.

, International nonproprietary names (INN) for biological and biotechnological substances (a review), 2016.

G. Levy-clarke, D. A. Jabs, and R. W. Read, Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders, Ophthalmology, vol.121, pp.785-796, 2014.

B. Scallon, A. Cai, and N. Solowski, Binding and functional comparisons of two types of tumor necrosis factor antagonists, J Pharmacol Exp Ther, vol.301, pp.418-426, 2002.

E. Miserocchi, G. Modorati, and I. Pontikaki, Long-term treatment with golimumab for severe uveitis, Ocul Immunol Inflamm, vol.22, pp.90-95, 2014.

M. William, S. Faez, and G. N. Papaliodis, Golimumab for the treatment of refractory juvenile idiopathic arthritisassociated uveitis, J Ophthalmic Inflamm Infect, vol.2, pp.231-233, 2012.

M. Mesquida, V. Hernandez, M. Llorenc, and V. , Behcet disease-associated uveitis successfully treated with golimumab, Ocul Immunol Inflamm, vol.21, pp.160-162, 2013.

E. Miserocchi, G. Modorati, and I. Pontikaki, Golimumab treatment for complicated uveitis, Clin Exp Rheumatol, vol.31, pp.320-321, 2013.

M. Cordero-coma, D. Salom, and M. Diaz-llopis, Golimumab for uveitis, Ophthalmology, vol.118, p.1892, 2011.

S. Dhillon, Certolizumab pegol: a review of its use in patients with axial spondyloarthritis or psoriatic arthritis, Drugs, vol.74, pp.999-1016, 2014.

R. Landewe, J. Braun, and A. Deodhar, Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study, Ann Rheum Dis, vol.73, pp.39-47, 2014.

V. Llorenc, M. Mesquida, and M. Sainz-de-la-maza, Certolizumab pegol, a new anti-TNF-alpha in the armamentarium against ocular inflammation, Ocul Immunol Inflamm, vol.2015, pp.1-6

J. Keane, G. S. Wise, and R. P. , Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent, N Engl J Med, vol.345, pp.1098-1104, 2001.

W. G. Dixon, K. L. Hyrich, and K. D. Watson, Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for, Rheumatology Biologics Register

, Ann Rheum Dis, vol.69, pp.522-528, 2009.

F. Tubach, D. Salmon, and P. Ravaud, Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry, Arthritis Rheum, vol.60, pp.1884-1894, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00618680

J. W. Ai, S. Zhang, and Q. L. Ruan, The risk of tuberculosis in patients with rheumatoid arthritis treated with tumor necrosis factor-alpha antagonist: A metaanalysis of both randomized controlled trials and registry/cohort studies, J Rheumatol, vol.42, pp.2229-2237, 2015.

I. Simsek, H. Erdem, and S. Pay, Optic neuritis occurring with anti-tumour necrosis factor alpha therapy, Ann Rheum Dis, vol.66, pp.1255-1258, 2007.

E. T. Cunningham and M. Zierhut, TNF inhibitors for uveitis: balancing efficacy and safety, Ocul Immunol Inflamm, vol.18, pp.421-423, 2010.

J. P. Stubgen, Tumor necrosis factor-alpha antagonists and neuropathy, Muscle Nerve, vol.37, pp.281-292, 2008.

A. J. Solomon, R. I. Spain, and M. C. Kruer, Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors, Mult Scler, 2011.

L. Bensouda-grimaldi, D. Mulleman, and J. P. Valat, Adalimumab-associated multiple sclerosis, J Rheumatol, vol.34, pp.239-240, 2007.

T. Ding, J. Ledingham, and R. Luqmani, BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies, Rheumatology (Oxford), vol.49, pp.2217-2219, 2010.

R. Pereira, P. Lago, and R. Faria, Safety of Anti-TNF Therapies in Immune-Mediated Inflammatory Diseases: Focus on Infections and Malignancy, 2015.

J. Gueudry,

, Ocular Immunology & Inflammation

F. Atzeni, L. Gianturco, and R. Talotta, Investigating the potential side effects of anti-TNF therapy for rheumatoid arthritis: cause for concern?, Immunotherapy, vol.7, pp.353-361, 2015.

E. L. Williams, S. Gadola, and C. J. Edwards, Anti-TNF-induced lupus, Rheumatology (Oxford), vol.48, pp.716-720, 2009.

F. Atzeni, R. Talotta, and F. Salaffi, Immunogenicity and autoimmunity during anti-TNF therapy, Autoimmun Rev, vol.12, pp.703-708, 2013.

A. I. Catrina, C. Trollmo, and E. Klint, Evidence that antitumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report, Arthritis Rheum, vol.52, pp.61-72, 2005.

D. Iwata, K. Namba, and K. Mizuuchi, Correlation between elevation of serum antinuclear antibody titer and decreased therapeutic efficacy in the treatment of Behcet's disease with infliximab, Graefes Arch Clin Exp Ophthalmol, vol.250, pp.1081-1087, 2012.

D. Pascual-salcedo, C. Plasencia, and S. Ramiro, Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis, Rheumatology (Oxford), vol.50, pp.1445-1452, 2011.

P. J. Hashkes and I. Shajrawi, Sarcoid-related uveitis occurring during etanercept therapy, Clin Exp Rheumatol, vol.21, pp.645-646, 2003.

G. Sturfelt, B. Christensson, and G. Bynke, Neurosarcoidosis in a patient with rheumatoid arthritis during treatment with infliximab, J Rheumatol, vol.34, pp.2313-2314, 2007.

C. I. Daien, A. Monnier, and P. Claudepierre, Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases, Rheumatology (Oxford), vol.48, pp.883-886, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00465169

G. H. Louie, P. Chitkara, and M. M. Ward, Relapse of sarcoidosis upon treatment with etanercept, Ann Rheum Dis, vol.67, pp.896-898, 2008.

C. Joyau, G. Veyrac, and V. Dixneuf, Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect?, Clin Exp Rheumatol, vol.30, pp.700-706, 2012.

L. L. Lim, F. W. Fraunfelder, and J. T. Rosenbaum, Do tumor necrosis factor inhibitors cause uveitis? A registry-based study, Arthritis Rheum, vol.56, pp.3248-3252, 2007.

T. Cobo-ibanez, C. Ordonez, M. Munoz-fernandez, and S. , Do TNF-blockers reduce or induce uveitis?, Rheumatology (Oxford), vol.47, pp.731-732, 2008.

R. Scrivo, A. Spadaro, and F. R. Spinelli, Uveitis following the use of tumor necrosis factor alpha inhibitors: comment on the article by, Arthritis Rheum, vol.58, pp.1556-1557, 2008.

V. Kakkassery, S. Mergler, and U. Pleyer, Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? observational report on six patients: occurrence of uveitis following etanercept treatment, Curr Eye Res, vol.35, pp.751-756, 2010.

A. R. Reddy and O. C. Backhouse, Does etanercept induce uveitis?, Br J Ophthalmol, vol.87, p.925, 2003.

M. Taban, W. J. Dupps, and B. Mandell, Etanercept (enbrel)-associated inflammatory eye disease: case report and review of the literature, Ocul Immunol Inflamm, vol.14, pp.145-150, 2006.

A. N. Tiliakos and N. A. Tiliakos, Ocular inflammatory disease in patients with RA taking etanercept: is discontinuation of etanercept necessary?, J Rheumatol, vol.30, p.2727, 2003.

O. Kaipiainen-seppanen and M. Leino, Recurrent uveitis in a patient with juvenile spondyloarthropathy associated with tumour necrosis factor alpha inhibitors, Ann Rheum Dis, vol.62, pp.88-89, 2003.

B. Bodaghi, E. Bui-quoc, and B. Wechsler, Therapeutic use of infliximab in sight threatening uveitis: retrospective analysis of efficacy, safety, and limiting factors, Ann Rheum Dis, vol.64, pp.962-964, 2005.

E. Kruithof, P. Kestelyn, and C. Elewaut, Successful use of infliximab in a patient with treatment resistant spondyloarthropathy related uveitis, Ann Rheum Dis, vol.61, p.470, 2002.

Y. El-shabrawi and J. Hermann, Anti-tumor necrosis factoralpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis, Ophthalmology, vol.109, pp.2342-2346, 2002.

M. Rudwaleit, E. Rodevand, and P. Holck, Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study, Ann Rheum Dis, vol.68, pp.696-701, 2009.

V. Calvo-rio, D. De-la-hera, and R. Blanco, Golimumab in uveitis previously treated with other anti-TNF-alpha drugs: a retrospective study of three cases from a single centre and literature review, Clin Exp Rheumatol, vol.32, pp.864-868, 2014.

S. Faez, A. M. Lobo, and L. Sobrin, Treatment of seronegative spondyloarthropathy-associated uveitis with golimumab: retrospective case series, Clin Experiment Ophthalmol, vol.42, pp.392-395, 2014.

M. Cordero-coma, V. Calvo-rio, and A. A. , Golimumab as rescue therapy for refractory immune-mediated uveitis: a three-center experience, Mediators Inflamm, p.717598, 2014.

S. G?mez, M. Calvo-río, V. Blanco, and R. , AB0747 Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 9 patients, Annals of the Rheumatic Diseases, vol.74, p.1149, 2015.

S. Guignard, L. Gossec, and C. Salliot, Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study, Ann Rheum Dis, vol.65, pp.1631-1634, 2006.

J. Braun, X. Baraliakos, and J. Listing, Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept, Arthritis Rheum, vol.52, pp.2447-2451, 2005.

D. Wendling, A. Joshi, and P. Reilly, Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database, Curr Med Res Opin, vol.30, pp.2515-2521, 2014.

P. Brito-zeron, R. Perez-alvarez, and M. Ramos-casals, Etanercept and uveitis: friends or foes, Curr Med Res Opin, vol.31, pp.251-252, 2015.

M. Rudwaleit, J. T. Rosenbaum, and R. Landewe, Observed incidence of uveitis following certolizumab pegol treatment in patients with axial spondyloarthritis, Arthritis Care Res (Hoboken), vol.68, pp.838-844, 2016.

J. Gueudry, P. Lehoang, and B. Bodaghi, Anti-tumor necrosis factor-alpha agents in noninfectious uveitis, Dev Ophthalmol, vol.51, pp.63-78, 2012.

D. Wu, Y. Y. Guo, and N. N. Xu, Efficacy of anti-tumor necrosis factor therapy for extra-articular manifestations in patients with ankylosing spondylitis: a meta-analysis, BMC Musculoskelet Disord, vol.16, p.19, 2015.

D. Van-der-heijde, D. Silva, J. C. Dougados, and M. , Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis, Ann Rheum Dis, vol.65, pp.1572-1577, 2006.

H. Marzo-ortega, D. Mcgonagle, and S. Jarrett, Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study, Ann Rheum Dis, vol.64, pp.1568-1575, 2005.

J. Brandt, A. Khariouzov, and J. Listing, Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis, Arthritis Rheum, vol.48, pp.1667-1675, 2003.

J. C. Davis, D. Van-der-heijde, and J. Braun, Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial, Arthritis Rheum, vol.48, pp.3230-3236, 2003.

J. E. Paramarta and D. Baeten, Spondyloarthritis: from unifying concepts to improved treatment, Rheumatology (Oxford), vol.53, pp.1547-1559, 2014.

N. Yeremenko, J. E. Paramarta, and D. Baeten, The interleukin-23/ interleukin-17 immune axis as a promising new target in the treatment of spondyloarthritis, Curr Opin Rheumatol, vol.26, pp.361-370, 2014.

T. Pham, Pathophysiology of ankylosing spondylitis: what's new?, Joint Bone Spine, vol.75, pp.656-660, 2008.

S. Jawad, B. Liu, and E. Agron, Elevated serum levels of interleukin-17A in uveitis patients, Ocul Immunol Inflamm, vol.21, pp.434-439, 2013.

A. Amadi-obi, C. R. Yu, and X. Liu, TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1, Nat Med, vol.13, pp.711-718, 2007.

F. Van-den-bosch and A. Deodhar, Treatment of spondyloarthritis beyond TNF-alpha blockade, Best Pract Res Clin Rheumatol, vol.28, pp.819-827, 2014.

W. Hueber, D. D. Patel, and T. Dryja, Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis, Sci Transl Med, vol.2, pp.52-72, 2010.

A. D. Dick, I. Tugal-tutkun, and S. Foster, Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology, vol.120, pp.777-787, 2013.

E. Letko, S. Yeh, and C. S. Foster, Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy

, Ophthalmology, vol.122, pp.939-948, 2015.

D. Baeten, J. Sieper, and J. Braun, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis, N Engl J Med, vol.373, pp.2534-2548, 2015.

D. Baeten, X. Baraliakos, and J. Braun, Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial, Lancet, vol.382, pp.1705-1713, 2013.

P. J. Mease, I. B. Mcinnes, and B. Kirkham, Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis, N Engl J Med, vol.373, pp.1329-1339, 2015.

I. B. Mcinnes, P. J. Mease, and B. Kirkham, Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, doubleblind, placebo-controlled, phase 3 trial, Lancet, vol.386, pp.1137-1146, 2015.

A. L. Tan, H. Marzo-ortega, O. Connor, and P. , Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study, Ann Rheum Dis, vol.63, pp.1041-1045, 2004.

H. Haibel, M. Rudwaleit, and J. Listing, Open label trial of anakinra in active ankylosing spondylitis over 24 weeks, Ann Rheum Dis, vol.64, pp.296-298, 2005.

J. Sieper, B. Porter-brown, and L. Thompson, Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebocontrolled trials, Ann Rheum Dis, vol.73, pp.95-100, 2014.

J. Sieper, J. Braun, and J. Kay, Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind

, Ann Rheum Dis, vol.74, pp.1051-1057, 2015.

A. Muselier, P. Bielefeld, and S. Bidot, Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis, Ocul Immunol Inflamm, vol.19, pp.382-383, 2011.
URL : https://hal.archives-ouvertes.fr/hal-01183023

M. Papo, P. Bielefeld, and H. Vallet, Tocilizumab in severe and refractory non-infectious uveitis, Clin Exp Rheumatol, vol.32, pp.75-79, 2014.

M. Mesquida, B. Molins, and V. Llorenc, Long-term effects of tocilizumab therapy for refractory uveitis-related macular edema, Ophthalmology, vol.121, pp.2380-2386, 2014.

A. Adan, M. Mesquida, and V. Llorenc, Tocilizumab treatment for refractory uveitis-related cystoid macular edema, Graefes Arch Clin Exp Ophthalmol, vol.251, pp.2627-2632, 2013.

A. Adan, M. Mesquida, and V. Llorenc, Tocilizumab for retinal vasoproliferative tumor secondary to juvenile idiopathic arthritis-associated uveitis: a case report, Graefes Arch Clin Exp Ophthalmol, vol.252, pp.163-164, 2014.

T. Hirano, N. Ohguro, and S. Hohki, A case of Behcet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab, Mod Rheumatol, vol.22, pp.298-302, 2012.

V. Calvo-rio, D. De-la-hera, and E. Beltran-catalan, Tocilizumab in uveitis refractory to other biologic drugs: a study of 3 cases and a literature review, Clin Exp Rheumatol, vol.32, pp.54-57, 2014.

D. Wendling, E. Dernis, and C. Prati, Onset of inflammatory eye disease under tocilizumab treatment for rheumatologic conditions: a paradoxical effect?, J Rheumatol, vol.38, p.2284, 2011.

I. H. Song, F. Heldmann, and M. Rudwaleit, Different response to rituximab in tumor necrosis factor blockernaive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial, Arthritis Rheum, vol.62, pp.1290-1297, 2010.

I. H. Song, F. Heldmann, and M. Rudwaleit, Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study, Ann Rheum Dis, vol.70, pp.1108-1110, 2011.

P. Mease, M. C. Genovese, and G. Gladstein, Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial, Arthritis Rheum, vol.63, pp.939-948, 2011.

C. Ambarus, N. Yeremenko, and P. P. Tak, Pathogenesis of spondyloarthritis: autoimmune or autoinflammatory?, Curr Opin Rheumatol, vol.24, pp.351-358, 2012.